MRNA-4359 is under clinical development by Moderna and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to GlobalData, Phase II drugs for Triple-Negative Breast Cancer (TNBC) have a 25% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how MRNA-4359’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
mRNA-4359 is under development for the treatment of advanced or metastatic solid tumors including cutaneous melanoma, non-muscle invasive bladder cancer, head and neck squamous cell carcinoma, microsatellite stable colorectal cancer (MSS CRC), basal cell carcinoma, triple negative breast cancer and non-small cell lung carcinoma (NSCLC). The therapeutic candidate is an mRNA vaccine. It acts by targeting indoleamine 2,3 dioxygenase (IDO) and programmed death-ligand 1 (PD-L1) antigens. It is administered through intramuscular route.
Moderna operates as a developer of messenger RNA therapeutics. The company develops and discovers drugs that produce proteins or antibodies inside patient cells. Its pipeline includes various drug modalities such as prophylactic vaccines, therapeutic vaccines, intratumoral immuno-oncology, localized therapeutics, and liver intracellular. Moderna through its mRNA therapeutics platform develops and produces human proteins, antibodies, and novel proteins, which help in preventing, treating, and curing diseases. It also develops therapeutics in the areas of infectious disease, rare liver disease, immuno-oncology, and cardiovascular disease. Moderna Therapeutics is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of MRNA-4359’s drug-specific PTSR and LoA scores, buy the report here.